The following antibodies were purchased from Cell Signaling Technology: Akt(#4691),
Phospho-Akt(Thr308)(#4056),
Phospho-Akt(Ser473)(#4060),
GAPDH,
GSK-3β(#9315), Phospho-
GSK-3β(#9323),
FoxO1(#2880), Phospho-
FoxO1 (Thr24)/
FoxO3a(Thr32)/FoxO4(Thr28)(#2599),
PRAS40(#2691), Phospho-
PRAS40 (Thr246)(#2997),
4E-BP1(#9644),
p70 S6K(#2708), Phospho-
p70 S6K (Thr389)(#9234). SQSTM1/p62 (D5E2)(#8025), LC3B(#12513). PARP(#9532), Caspase-3(#9665), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)(#4377), p44/42 MAPK (Erk1/2) (#4695), Phospho-NF-ΚB P65 (Ser 536)(#3033), NF-ΚB P65(#4764).
Lysophosphatidic Acid (#sc-201053, Santa Cruz),
Recombinant Human PDGF-BB (#220-BB, R&D),
Recombinant Human C5a (Peprotech, #300-70), goat anti-IgM (#5C07615, Meridian). LC3B antibody (#3868, CST).
Tubulin antibody (#8035, Santa Cruz).
EEA1 antibody (#610456, BD Bioscience) and
LAMP1 antibody (#24170, Abcam). Secondary antibodies,
Alexa488-anti-mouse,
Alexa594-anti-rabbit and
Prolong gold mounting medium with DAPI were purchased from Invitrogen.
Liu X., Wang A., Liang X., Liu J., Zou F., Chen C., Zhao Z., Deng Y., Wu H., Qi Z., Wang B., Wang L., Liu F., Xu Y., Wang W., Fernandes S.M., Stone R.M., Galinsky I.A., Brown J.R., Loh T., Griffin J.D., Zhang S., Weisberg E.L., Zhang X., Liu J, & Liu Q. (2016). Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget, 7(33), 53515-53525.